['renal cell carcinoma']
['atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody', 'bevacizumab', 'sunitinib']

        Inclusion Criteria:

          -  Definitive diagnosis of unresectable locally advanced or metastatic RCC with
             clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior
             treatment in the metastatic setting

          -  Evaluable Memorial Sloan Kettering Cancer Center risk score

          -  Measurable disease, as defined by RECIST v1.1

          -  Karnofsky performance status greater than or equal to 70%

          -  Adequate hematologic and end-organ function prior to randomization

        Exclusion Criteria:

        Disease-Specific Exclusions:

          -  Radiotherapy for RCC within 14 days prior to treatment

          -  Active central nervous system disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites

          -  Uncontrolled hypercalcemia

          -  Any other malignancies within 5 years except for low-risk prostate cancer or those
             with negligible risk of metastasis or death

        General Medical Exclusions:

          -  Life expectancy less than 12 weeks

          -  Participation in another experimental drug study within 4 weeks prior to treatment

          -  Pregnant or lactating women

          -  Known hypersensitivity to any component of atezolizumab or other study medication

          -  History of autoimmune disease except controlled, treated hypothyroidism or type I
             diabetes mellitus

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis

          -  Positive human immunodeficiency virus test

          -  Active or chronic hepatitis B or C

          -  Severe infections within 4 weeks prior to treatment

          -  Exposure to oral or IV antibiotics within 2 weeks prior to treatment

          -  Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination
             participants must agree not to receive live, attenuated influenza vaccine within 4
             weeks prior to treatment, during treatment or within 5 months following the last dose)

          -  Significant cardiovascular disease

          -  Prior allogeneic stem cell or solid organ transplantation

        Exclusion Criteria Related to Medications:

          -  Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic
             T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1
             therapeutic antibody or pathway-targeting agents

          -  Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or
             immunosuppressive agents within 2 weeks prior to treatment

        Bevacizumab- and Sunitinib-Specific Exclusions:

          -  History of hypertensive crisis or hypertensive encephalopathy

          -  Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds
      